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Background
Effective management of peripheral viral loads with anti-
retroviral drugs can delay or halt CD4 cell loss for dec-
ades. However, patients still face the potential of devel-
oping significant HIV-1 associated neurocognitive
disorders (HAND). Challenges obtaining relevant clinical
samples limit the detailed investigation of the aetiology
and neuropathology of HAND and therefore we do not
understand the impact of vaccines that confer partial
protection on long term neuropathology.
Methods
We are using immunohistochemical analysis of brain
sections from the experimental infection of macaques
with SIV to model neuropathology in situations where
peripheral viral loads are under effective control.
Results
We have established that chronic infection with attenu-
ated SIV, where peripheral viral loads are below detec-
tion, still results in pathological changes (astrogliosis,
microglial activation, viral persistence). We have now
extended these studies using a unique conditional live
attenuated, doxycycline dependent virus, SIVrtTA.
Removal of doxycycline 3 weeks after infection, at the
end of the primary viremia results in detectable neuro-
pathological changes in astrocytes, oligodendrocytes,
microglia and perivascular macrophage 40 weeks later.
We are also investigating the effects of vaccines that
confer partial protection on the neuropathology of wild-
type SIV infection. A vaccine study using SIV Gag based
vaccines comprising three primes with rDNAgag followed
by a rAdgag boost resulted in significant delay in acquisi-
tion of SIVmac251 administered by low-dose intra-rectal
challenge. Furthermore, there was a significant blunting
of the primary viremia, but no significant suppression of
set-point viral loads compared with naive challenge con-
trols. We are determining the impact of vaccination on
the frequency of virus infected cells in the brain collected
20-30 weeks after infection and also comparing the fre-
quency and intensity of neuropathological changes in
infected vaccinated and control macaques.
Conclusion
These data will enable us to establish the likely neurolo-
gical benefit of vaccines that do not provide protection
against detectable infection.
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